ATYR Investors: Securities Law Firm Robbins LLP Reminds Investors of the Pending Lead Plaintiff Deadline in the Class Action Against aTyr Pharma, Inc.

Core Viewpoint - aTyr Pharma, Inc. is facing a class action lawsuit due to allegations of misleading investors regarding the efficacy of its drug candidate, Efzofitimod, during a clinical trial for pulmonary sarcoidosis [1][3]. Company Overview - aTyr Pharma, Inc. is a clinical stage biotechnology company focused on developing therapies for fibrosis and inflammation through tRNA synthetase biology [1]. Legal Allegations - The lawsuit claims that aTyr's executives provided misleading information about the Phase 3 study of Efzofitimod, particularly regarding the forced taper approach and the drug's ability to reduce steroid usage in patients [3]. - On September 15, 2025, aTyr announced that the EFZO-FIT study did not meet its primary endpoint, leading to a significant drop in stock price from $6.03 to $1.02, an 83.2% decline in one day [4]. Next Steps - Shareholders interested in participating in the class action must submit their papers by December 8, 2025, to serve as lead plaintiff [5].